Eli Lilly and Co Stock Price Could Go Down After Today’s Bearish Options Activity

 Eli Lilly and Co Stock Price Could Go Down After Today's Bearish Options Activity

In today’s session Eli Lilly and Co (LLY) recorded an unusually high (1,000) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious LLY decrease. With 1,000 contracts traded and 9874 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: LLY170120P00085000 closed last at: $8.75 or 5.4% down. About 493,648 shares traded hands. Eli Lilly and Co (NYSE:LLY) has risen 9.58% since March 2, 2016 and is uptrending. It has outperformed by 1.32% the S&P500.

Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on October, 25 before the open. They expect $0.94 earnings per share, up 5.62% or $0.05 from last year’s $0.89 per share. LLY’s profit will be $1.04 billion for 21.76 P/E if the $0.94 EPS becomes a reality. After $0.86 actual earnings per share reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 9.30% EPS growth.

Eli Lilly and Co (NYSE:LLY) Ratings Coverage

Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. $125 is the highest target while $75 is the lowest. The $97.88 average target is 19.67% above today’s ($81.79) stock price. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, September 18 by Jefferies. The firm earned “Outperform” rating on Monday, December 28 by Leerink Swann. The firm has “Buy” rating by Berenberg given on Thursday, August 27. The rating was initiated by Atlantic Securities on Friday, December 18 with “Overweight”. The rating was maintained by Leerink Swann on Monday, May 2 with “Outperform”. The firm has “Outperform” rating given on Tuesday, December 8 by Credit Suisse. Societe Generale initiated the stock with “Hold” rating in Wednesday, April 6 report. Leerink Swann maintained the shares of LLY in a report on Thursday, November 12 with “Outperform” rating. Goldman Sachs upgraded the stock to “Buy” rating in Tuesday, September 27 report. The firm earned “Buy” rating on Thursday, July 14 by Jefferies.

According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”

Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.36, from 0.71 in 2016Q1. The ratio is positive, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Spears Abacus Advisors Ltd Liability Corp holds 0.06% of its portfolio in Eli Lilly and Co (NYSE:LLY) for 6,350 shares. Nelson Roberts Invest Advisors Ltd Liability Com accumulated 0.02% or 563 shares. The Massachusetts-based Acadian Asset Management has invested 0.01% in Eli Lilly and Co (NYSE:LLY). Umb Bank N A Mo last reported 66,590 shares in the company. Suntrust Banks holds 0.09% or 183,510 shares in its portfolio. Firstmerit Bancorp N A Trustee has 0.16% invested in the company for 25,097 shares. Grandfield & Dodd Ltd Liability Co last reported 7,761 shares in the company. Garde Capital holds 2,550 shares or 0.07% of its portfolio. Clifford Swan Counsel Limited Liability Co has invested 0.03% of its portfolio in Eli Lilly and Co (NYSE:LLY). Liberty Mutual Grp Incorporated Asset Management Incorporated last reported 68,594 shares in the company. Wilkins Inv Counsel accumulated 0.1% or 3,740 shares. Laffer Invs, a Tennessee-based fund reported 26,819 shares. Fincl Bank has invested 0.06% of its portfolio in Eli Lilly and Co (NYSE:LLY). Tci Wealth has invested 0.64% of its portfolio in Eli Lilly and Co (NYSE:LLY). Hartford Finance Inc owns 267 shares or 0.01% of their US portfolio.

Insider Transactions: Since April 8, 2016, the stock had 1 insider buy, and 13 sales for $149.42 million net activity. The insider LILLY ENDOWMENT INC sold $15.02M. Zakrowski Donald A also sold $100,873 worth of Eli Lilly and Co (NYSE:LLY) on Thursday, July 28. Barnes Melissa S sold $73,180 worth of stock. Shares for $205,875 were bought by TAI JACKSON P on Friday, August 12. Zulueta Alfonso G had sold 12,000 shares worth $915,240.

Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $90.41 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 35.25 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

LLY Company Profile

Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.

More recent Eli Lilly and Co (NYSE:LLY) news were published by: Streetinsider.com which released: “Eli Lilly & Co. (LLY) Unit to Acquire Rabies Vaccine Portfolio from Boehringer …” on October 05, 2016. Also Schaeffersresearch.com published the news titled: “Analyst Upgrades: Twitter Inc, Array Biopharma Inc, and Eli Lilly and Co” on September 27, 2016. Streetinsider.com‘s news article titled: “Eli Lilly & Co. (LLY) to Present Data for Taltz in Psoriasis at EADV” with publication date: September 27, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment